DANBURY, Conn.--(BUSINESS WIRE)--Biodel Inc. (Nasdaq: BIOD) today reported positive effects of VIAject™ insulin on microvascular function in patients with Type 2 diabetes which were superior to results seen with regular human insulin and insulin lispro. Professor Thomas Forst, MD, Institute for Clinical Research and Development (IKFE), Mainz, Germany, and principal investigator of the study, presented the findings today at the Eighth Annual Diabetes Technology Meeting in Bethesda, MD.
